Vatech America competitors

John has over 20 years of healthcare experience with 10 years directly in the cancer field. He is a board member or trusted advisor on active investments in Cancer, Dermatology, Diabetes, Anatomical Pathology, Generic Pharmaceuticals, Nuclear Pharmaceuticals, Health Payments and Health Information Technology through Bioveda China Fund, Amorperum Health and with a small number of top tier Private Equity Healthcare Firms. He is very active in board roles with a variety of healthcare companies in Israel, China, India and the US. Some of his past boards include Prodigy Health, which sold to Aetna (NYSE:AET) , and CITIC Pharmaceuticals, which sold to Shanghai Pharmaceuticals (SH:601607). Previously, John was the CEO of Oncology Therapeutics Network, which sold to McKesson, President of Oncology Services at Bristol Myers Squibb, and a Vice President at McKesson. He was a co- founder of Cancer Centers of Excellence and an early investor in Oncology Molecular Imaging. John studied economics and physics at University of California at Davis and has a Bachelor of Science from University of the State of New York. John served for 12 years in the United States Air Force and Air National Guard. He is currently a member of YPO and is active with the Wounded Warrior Project.

John Fraher is a Chief Executive Officer at Aptalis Pharma Inc, Chief Executive Officer at Eurand NV, and Board Member at Ellodi Pharmaceuticals and is based in United States. He has worked as Pres:Aptalis Pharma Technologies at Aptalis Pharma Inc, Production Manager at Fort Dodge Animal Health, and President at Aptalis Pharma Inc. John works or has worked as President:America at Eurand Pharmaceuticals Hldg. He attended University College Dublin between 1984 and 1989.

Mr. Martin is the founding partner of ACM Capital Partners, LLC, a lower to middle-market turnaround firm headquartered in Miami, Florida. Under Martin’s leadership, the firm has restructured or refinanced over $1.1 billion of senior, junior and mezzanine debt since its inception in October 2008, spanning 90 engagements. Prior to launching ACM, Martin was the CFO and then President of Avborne, Inc., a $100 million aviation maintenance repair and overhaul operation in Miami, Florida which was hard hit by the events of September 11th. While at Avborne, he successfully restructured $123 million of debt and ultimately revitalized both of the company’s divisions and sold them for an average selling price of 10x EBITDA or $138 million. Martin began his career as a commercial lender for a regional bank in 1984 and later joined TotalBank where he successfully restructured a premium finance subsidiary. Martin, a CPA, earned a BS in Finance from Florida State University and an MBA from Emory University’s Goizueta Business School.

Gary Phillips was appointed Chief Executive Officer and a member of the Pharmaxis Board of Directors in March 2013. Mr Phillips joined Pharmaxis in December 2003 when the company listed on the Australian Securities Exchange. He served as Commercial Director until June 2008 when he was appointed the company’s Chief Operating Officer. In this role he expanded Pharmaxis’ Commercial infrastructure in Europe and the USA, and worked closely with the clinical development, regulatory approval processes and reimbursement of Pharmaxis products Aridol and Bronchitol. Mr Phillips has more than 30 years of operational management experience in the pharmaceutical and healthcare industry in Europe, Asia and Australia. From 1998 to 2003, Mr. Phillips held various positions within Novartis Asia Pacific, first as a Regional Manager responsible for the P&L of 8 countries and most recently as Chief Executive Officer of Novartis Pharmaceuticals Australia Pty Ltd, where he successfully launched leading oncology and ophthalmology products and relaunched newly acquired primary care products. From 1992 to 1998, Mr. Phillips served as Chief Executive Officer at Ciba Geigy in Hungary (Merged to form Novartis in 1996) where he led the launch of multiple new products and achieved the leading market share amongst multinational pharmaceutical companies. Gary Phillips holds a B. Pharm. in Pharmacy with honors from Nottingham University in the U.K. and an M.B.A. from Henly Management College.

Experienced Chief Executive Officer with a demonstrated history of working in the aesthetic, health care, and pharmaceutical industries. Strong legal and business professional skilled in Strategic Planning, Enhanced Valuation Strategies, M&A Activities, Intellectual Property and Brand Protection and Medical Compliance.